Related Experiment Videos
[Multiple myeloma]
Summary
Multiple myeloma treatment progress has been slow, with limited advances beyond older chemotherapy drugs. Future strategies require understanding individual myeloma biology for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Context:
- Multiple myeloma treatment has seen slow progress since the introduction of melphalan and cyclophosphamide over two decades ago.
- Current therapeutic strategies face limitations in overcoming chemotherapy resistance.
- Understanding the biological properties of individual myeloma cases is crucial for advancing treatment.
Purpose:
- To review the progress and challenges in multiple myeloma treatment up to 1988.
- To discuss various aspects of multiple myeloma management, including survival, remission, variant forms, and complications.
- To highlight the need for personalized therapeutic strategies.
Summary:
- This review covers ten-year survival, complete remission rates, and management of specific multiple myeloma subtypes and complications.
- It addresses treatments for resistant cases, IgD myeloma, elderly patients, extramedullary plasmacytoma, and smoldering multiple myeloma.
- The outcome of idiopathic Bence Jones proteinuria and supportive therapies are also discussed.
Impact:
- Identifies the slow pace of progress in multiple myeloma treatment, emphasizing the need for novel therapeutic approaches.
- Underscores the importance of individualized treatment strategies based on the biological characteristics of each patient.
- Provides a historical overview of multiple myeloma management challenges and potential future directions.